Search Main Menu Main Content

Choose language
Change contrast :
Standards Reinforced

icone

HAS profile

Mission
Organisational Structure
Ethics, transparency and management of conflicts of interest

International relations and projects
Publications

Recherche

icone plus
My account

Email alert Subscription

Newsletter Subscription

My search

Refresh

Please fill in your email address to retrieve your email alerts subscriptions.

New subscription

Please fill in your email address to retrieve your newsletter subscriptions.

You do not have a saved search
No element in selection
Contact

1 result

Active substance : alcool
Active substance : lithium
Active substance : gabapentine
Active substance : sufentanil
Active substance : potassium
Type : Drugs, devices and medical acts

Topic

Diagnostic and therapeutic techniques (1)
Plus ...

Drugs, devices and medical acts (1)
Plus ...
- Health technology assessment (1)

Date

This year (1)

inconnu (1)
industriels (1)

Français (1)

Active substance

alcool (1)
amitriptyline (1)
amoxicilline (1)
cabergoline (1)
dimercaprol (1)
fentanyl (1)
fluconazole (1)
gabapentine (1)
glucosamine (1)
hydromorphone (1)
influenzinum (1)
itraconazole (1)
lithium (1)
morphine (1)
nadolol (1)
oxycodone (1)
piroxicam (1)
potassium (1)
propranolol (1)
sodium (1)
succimer (1)
sufentanil (1)
sulfasalazine (1)
topiramate (1)
venlafaxine (1)
zinc (1)

Drugs, devices and medical acts

Première page
Page précédente
/ 1
Page suivante
Dernière page

Sorted by :Relevance

Title
Date

Assesment of homeopathic medicines

Health technology assessment - Posted on 07/09/2019

Download document

Add to my selection

Première page
Page précédente
/ 1
Page suivante
Dernière page
10 par pages

Advancing quality in the fields of health and social care services

Follow us :

Eunetha.eu
Pasq.eu

All our publications by topic and type

Opinions on medicines
Opinions on medical devices
INAHTA briefs

Français
English

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

NY4dwFhrY7AYtgdB